{"doi":"10.18632/oncotarget.11044","title":"Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer","abstract":null,"journal":"Oncotarget","year":2017,"id":626215,"datarank":0.5606504427425053,"base_score":3.7376696182833684,"endowment":3.7376696182833684,"self_citation_contribution":0.5606504427425053,"citation_network_contribution":0.0,"self_endowment_contribution":0.5606504427425053,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":41,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1366822,"name":"Tianxiang Chen","orcid":"0000-0001-5199-7507","position":1,"is_corresponding":false},{"id":1619806,"name":"Guangliang Li","orcid":null,"position":2,"is_corresponding":false},{"id":1217213,"name":"Cong Xu","orcid":"0000-0002-5426-9721","position":3,"is_corresponding":false},{"id":419630,"name":"Zhenzhen Xu","orcid":"0000-0002-8755-8597","position":4,"is_corresponding":false},{"id":500806,"name":"Jing Zhang","orcid":"0000-0002-4823-4629","position":5,"is_corresponding":false},{"id":1619807,"name":"Kuifeng He","orcid":null,"position":6,"is_corresponding":false},{"id":1619808,"name":"Linyan Zheng","orcid":null,"position":7,"is_corresponding":false},{"id":1619809,"name":"Zhonghai Guan","orcid":null,"position":8,"is_corresponding":false},{"id":1619810,"name":"Xinyun Su","orcid":null,"position":9,"is_corresponding":false},{"id":1565578,"name":"Jiang Cao","orcid":null,"position":10,"is_corresponding":false},{"id":1619811,"name":"Lisong Teng","orcid":null,"position":11,"is_corresponding":false},{"id":735315,"name":"Yu Gu","orcid":"0000-0003-2353-063X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer","abstract":"// Yu Gu 1, 2 , Tianxiang Chen 3 , Guangliang Li 4 , Cong Xu 2 , Zhenzhen Xu 2 , Jing Zhang 2 , Kuifeng He 2 , Linyan Zheng 2 , Zhonghai Guan 2 , Xinyun Su 2 , Jiang Cao 5 and Lisong Teng 2 1 Department of Radiation Oncology, Shanghai Cancer Hospital, Fudan University, Shanghai, China 2 Department of Surgical Oncology, The 1st Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China 3 Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China 4 Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China 5 Clinical Research Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China Correspondence to: Lisong Teng, email: lsteng@zju.edu.cn Keywords: breast cancer, tamoxifen resistance, prognosis, beclin 1, HER2 Received: September 16, 2015     Accepted: June 29, 2016     Published: August 04, 2016 ABSTRACT Tamoxifen(TAM) is one of the most effective endocrine treatment for estrogen receptor(ER)-positive breast cancer, however drug resistance greatly limits benefit of it. Our purpose is to uncover the role of Beclin 1 in tamoxifen resistance and prognosis of ER positive breast cancer. We established a tamoxifen resistant ER-positive breast cancer cell subline MCF-7R presenting with higher Beclin 1 and human epidermal growth factor receptor 2(HER2) levels than MCF-7. Silencing Beclin 1 decreased levels of HER2 and significantly promoted TAM sensitivity of MCF-7 and MCF-7R in vitro . Overexpression of HER2 could reverse TAM sensitivity, which was formerly increased in Beclin 1 downregulated cell. Beclin 1 level was not only positively correlated with level of HER2 but also negatively correlated with overall survival of ER-positive breast cancer patients. Using bioinformatic methods, Beclin 1 mRNA was found to be negatively correlated with overall survival in breast cancer patients receiving TAM treatment. This study indicated for the first time that lower HER2 expression by Beclin 1 downregulation contributes to alteration of tamoxifen sensitivity and low Beclin 1 predicts favorable outcome in ER-positive breast cancer.","is_dataset_classified":null,"base_score":3.7376696182833684,"endowment":3.7376696182833684,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28881721","pmcid":"PMC5581020","openalex_id":"https://openalex.org/W2478630076","authors":[],"funders":[],"total_grants":0,"fwci":2.7256,"citation_percentile":0.90353541,"influential_citations":0,"citation_trend":[{"year":2017,"count":3},{"year":2018,"count":8},{"year":2019,"count":6},{"year":2020,"count":6},{"year":2021,"count":5},{"year":2022,"count":4},{"year":2023,"count":1},{"year":2024,"count":6},{"year":2025,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=11044&path%5B%5D=34971","host_type":"journal"},{"url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=11044&path%5B%5D=34971","host_type":"publisher"},{"url":"https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.11044","host_type":"publisher"},{"url":"https://doi.org/10.18632/oncotarget.11044","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28881721","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5581020","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC5581020","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC5581020?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Ubiquitin and proteasome pathways","Autophagy in Disease and Therapy","Histone Deacetylase Inhibitors Research"],"mesh_terms":[],"keywords":["Medicine","Tamoxifen","Breast cancer","Oncology","Internal medicine","Cancer","Cancer research","Prognosis","Her2","Tamoxifen Resistance","Beclin 1"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T12:53:45.575197Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}